Northland analyst Carl Byrnes named MiMedx a top pick for 2023, citing his view that the company is "well positioned to achieve 10%-14% topline growth for the foreseeable future." Growth is supported by capturing market share, entering into the $1B Surgical Recovery segment, the commercialization of new products and the launch of Epifix in Japan, said Byrnes, who has an Outperform rating and $16 price target on MiMedx shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MDXG:
- MiMedx in pact with Gunze for sales of EPIFIX in Japan
- MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
- MiMedx appoints Ricci Whitlow as COO
- MiMedx management to meet with Mizuho
- MiMedx announces Wound & Surgical product pipeline expansion
